Crystal structure of botulinum neuro-toxin type A and implications for toxicity

被引:610
|
作者
Lacy, DB
Tepp, W
Cohen, AC
DasGupta, BR
Stevens, RC [1 ]
机构
[1] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA
[2] Univ Calif Berkeley, Earnest Orlando Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA
[3] Univ Wisconsin, Dept Food Microbiol & Toxicol, Madison, WI 53706 USA
基金
美国国家科学基金会;
关键词
D O I
10.1038/2338
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Botulinum neurotoxin type A (BoNT/A) is the potent disease agent in botulism, a potential biological weapon and an effective therapeutic drug for involuntary muscle disorders. The crystal structure of the entire 1,285 amino acid di-chain neurotoxin was determined at 3.3 Angstrom resolution. The structure reveals that the translocation domain contains a central pair of alpha-helices 105 Angstrom long and a similar to 50 residue loop or belt that wraps around the catalytic domain. This belt partially occludes a large channel leading to a buried, negative active site - a feature that calls for radically different inhibitor design strategies from those currently used. The fold of the translocation domain suggests a mechanism of pore formation different from other toxins. Lastly, the toxin appears as a hybrid of varied structural motifs and suggests a modular assembly of functional subunits to yield pathogenesis.
引用
收藏
页码:898 / 902
页数:5
相关论文
共 50 条
  • [41] Botulinum toxin type A: from toxin to therapeutic agent
    Aoki, KR
    Ismail, M
    Tang-Liu, D
    Brar, B
    Wheeler, LA
    EUROPEAN JOURNAL OF NEUROLOGY, 1997, 4 : S1 - S3
  • [42] High-resolution crystal structure of HA33 of botulinum neurotoxin type B progenitor toxin complex
    Lee, Kwangkook
    Lam, Wok-Ho
    Kruel, Anna Magdalena
    Perry, Kay
    Rummel, Andreas
    Jin, Rongsheng
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 446 (02) : 568 - 573
  • [43] STUDIES OF THE TOXIN OF CLOSTRIDIUM BOTULINUM .4. FLUORESCENCE OF CLOSTRIDIUM BOTULINUM TOXIN AND ITS RELATION TO TOXICITY
    BOROFF, DA
    INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1959, 15 (1-3): : 74 - 90
  • [44] BOTULINUM TOXIN TYPE A IN CERVICAL DYSTONIA
    Marvulli, R.
    Ianieri, G.
    Megna, G.
    Lancioni, G.
    Saggini, R.
    Ranieri, M.
    Cristella, G.
    Megna, M.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2012, 25 : 23 - 28
  • [45] Botulinum toxin type B: an overview
    O'Brien, C
    OPTIMAL PATIENT MANAGEMENT WITH BOTULINUM TOXINS: EVIDENCE AND EXPERIENCE, 2002, (74): : 3 - 9
  • [46] The biochemistry of botulinum toxin type B
    Setler, P
    NEUROLOGY, 2000, 55 (12) : S22 - S28
  • [47] Botulinum toxin type A: applications in urogynaecology
    Sinha, Deepali
    Arunkalaivanan, Angamuthu S.
    OBSTETRICIAN & GYNAECOLOGIST, 2006, 8 (03): : 177 - 180
  • [48] Pharmacology of botulinum toxin type B
    Setler, PE
    EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 : 9 - 12
  • [49] Neurophysiological effects of botulinum toxin type a
    G. Abbruzzese
    A. Berardelli
    Neurotoxicity Research, 2006, 9 : 109 - 114
  • [50] Botulinum toxin type B micromechanosensor
    Liu, W
    Montana, V
    Chapman, ER
    Mohideen, U
    Parpura, V
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (23) : 13621 - 13625